| Value | ₹345.0 Cr |
|---|
NSE filing, NSE: CAPILLARY. Summary written from the filing by ALFA Finder's alert engine.
Capillary Technologies India Ltd: key numbers
- Share price
- ₹509.00
- Market cap
- ₹4,051 Cr
- Revenue (annual)
- ₹734.6 Cr
- Net profit (annual)
- ₹52.39 Cr
- P/E (TTM)
- 63.6×Sector 23.4×
- Promoter holding
- 47.23%-4.22% QoQ
- FII holding
- 2.56%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Capillary Technologies India Ltd
All →Capillary Technologies India Employee Stock Options
Capillary Technologies allotted 94,553 equity shares of ₹2 each upon exercise of vested ESOP 2021 options. The allotment was approved by circular resolution on November 04, 2026.
Capillary Technologies India Business Update
Capillary Technologies announced the strategic shutdown of its China operations due to low growth. Both quantitative and qualitative effects of the restructuring are stated as nil.
Capillary Technologies India Management Change
Capillary Technologies replaced internal auditor Protiviti with Deloitte Touche Tohmatsu India LLP on a 15-month term. The board cited expanding international operations as the reason.
Capillary Technologies India Other Announcement
Capillary Technologies appointed Deloitte Touche Tohmatsu India LLP as Internal Auditor, replacing Protiviti India. The change takes effect November 02, 2026.
Capillary Technologies India Results Update
Capillary announced Q2 FY27 revenue of ₹2,713.5 Mn (+51% YoY) and Adjusted EBITDA of ₹448.6 Mn (+103%). H1 FY27 revenue grew 47% with EBITDA up 116%.
Capillary Technologies India Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹2,713.5 Mn (+51% YoY), Adj. EBITDA ₹448.6 Mn (17% margin), PAT ₹219.2 Mn. H1 PAT ₹123.7 Mn after ₹333.9 Mn cyber-fraud exceptional loss. Organic NRR 116%.
Other fund raise announcements
All →Upsurge Investment & Finance Fund Raise of ₹20 Cr
Upsurge Investment & Finance approved unaudited Q2 FY27 results, appointed Manish Kabra as CFO, and approved raising up to Rs.20 Crore. The raise needs shareholder and regulatory approvals before proceeding.
- Value
- ₹20.00 Cr
Optiemus Infracom Fund Raise
Optiemus Infracom's board approved a fund raise, with mode and amount yet undecided. Details will follow after finalisation.
Jonjua Overseas Fund Raise of ₹14.7 Cr
Jonjua Overseas board approved raising up to Rs 14.70 crore more capital via a fund-raising committee. Board also noted a changed CIN and a paid BSE fine.
- Value
- ₹14.70 Cr
AGI Infra Fund Raise
AGI Infra shareholders approved a special resolution to raise funds via QIP through postal ballot. Votes in favour were 100% of votes polled; no amount stated.
Pajson Agro India Fund Raise of ₹354.5 Cr
Pajson Agro's board approved a Rs.354.52 Crore preferential issue of 1,20,58,397 equity shares at Rs.294 each. Shareholder approval is sought at a meeting on 04-12-2026.
- Value
- ₹354.5 Cr
Evonile Pharma Fund Raise of ₹900 Cr
Evonile Pharma's board approved a partly paid rights issue of up to Rs 900 Crore. A committee will set the issue price, record date and entitlement.
- Value
- ₹900.0 Cr